Cardinal Health stock slips as analysts raise price targets and earnings outlook stays solid

Published on 09/09/2026 at 14:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cardinal Health stock recently closed lower despite a solid earnings outlook for fiscal 2026 and rising analyst price targets as of September 8, 2026. Investors weigh the valuation premium against consensus forecasts for double-digit earnings growth.

Fotorealistisches Pharma-Distributionslager mit Gabelstapler und Mitarbeitern in Dublin Ohio — Cardinal Health Inc. betreibt ein modernes Pharma-Distributionslager in Dublin, Ohio – ISIN US14149Y1082, Illustration mit AI erstellt.

Cardinal Health stock (ISIN US14149Y1082) has eased back from recent highs, with the shares closing at USD 240.49 on the NYSE after a 2.71% decline from the prior session as of September 8, 2026, even as earnings expectations and analyst price targets continue to point to double-digit growth for the healthcare distributor.

Analysts see upside despite latest pullback

According to Yahoo Finance on September 8, 2026, Cardinal Health closed at USD 240.49, underperforming the S&P 500's 0.58% decline on the day, but still up 4.22% over the past month compared with a 2.73% gain in the Medical sector and a 0.36% loss in the broader index.

Against this price backdrop, several analyst houses have recently raised their price targets for the stock. As MarketBeat reports in an update dated September 9, 2026, Mizuho increased its price target from USD 240.00 to USD 250.00 and maintains an outperform rating, while JPMorgan Chase & Co. lifted its objective from USD 215.00 to USD 260.00 with a neutral stance.

The same overview from MarketBeat shows that sixteen analysts currently rate Cardinal Health stock as Buy and three as Hold, resulting in an average rating of Moderate Buy and an average price target of USD 266.56, implying upside of more than 10% from the recent closing level.

Consensus earnings forecasts support valuation

Fundamental expectations remain solid. In its coverage of the stock, Yahoo Finance cites Zacks Consensus Estimates for Cardinal Health's fiscal 2026, pointing to projected earnings per share of USD 12.55 and revenue of USD 266.02 billion, representing increases of 11.46% and 4.63%, respectively, versus the prior fiscal year.

Those growth rates help explain why valuation has moved to a premium relative to peers. The same analysis notes that Cardinal Health trades at a forward price-to-earnings ratio of about 19.7, above an industry forward P/E near 18.24, indicating investors are willing to pay a higher multiple for the expected earnings trajectory as of early September 2026.

A separate view from Zacks on September 8, 2026, similarly highlights that Cardinal Health trades at a forward P/E of about 19.2 times earnings, below the company's five-year high multiple of 22.19 times, and that consensus projections for fiscal 2027 earnings imply an 11.5% increase from the latest reported year.

Risks and what investors watch now

For investors, one key question is whether Cardinal Health can deliver on these double-digit earnings forecasts while maintaining margins in a competitive, low-spread distribution market. The consensus revenue growth of 4.63% for the current fiscal year is modest compared with the stronger projected EPS increase, suggesting efficiency gains, mix effects or capital allocation are expected to do part of the heavy lifting rather than pure top-line expansion.

The valuation premium versus the broader healthcare distribution space, with forward P/E ratios near 19 to 20 compared with an industry average around the high teens as of September 2026, leaves less room for disappointment if execution falters. At the same time, the fact that the stock is trading below its historical peak multiple of about 22 times, as noted by Zacks, offers some cushion if earnings growth materializes broadly in line with current forecasts.

The recent share-price pullback of 2.71% on September 8, 2026, following a one-month gain of 4.22%, can be seen as a pause after a period of outperformance, particularly as the broader S&P 500 index fell 0.58% on the same day and has declined over the past month. For investors, the combination of a Moderate Buy consensus, an average target of USD 266.56 and projected earnings growth of more than 11% reinforces Cardinal Health's positioning as a defensive healthcare name with a growth angle rather than a high-volatility momentum stock.

Stock level and market data snapshot

Cardinal Health stock closed at USD 240.49 on the NYSE on September 8, 2026, which is below the average analyst price target of USD 266.56 cited by MarketBeat, indicating upside of more than USD 26 per share if consensus assumptions are met.